Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.

$680.7M

Market Cap • 12/26/2024

2020

(4 years)
Founded

2021

(3 years ago)
IPO

NASDAQ

Listing Exchange
Flag of US

Durham

Headquarters • North Carolina